The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

John C. Davis

University of California

San Francisco

533 Parnassus Avenue

Box 0633

USA

[email]@*.ucsf.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of California, San Francisco, 533 Parnassus Avenue, Box 0633, USA. 2002 - 2008
  • Division of Rheumatology, UCSF 94143-0633, USA. 1999

References

  1. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Davis, J.C., van der Heijde, D.M., Braun, J., Dougados, M., Clegg, D.O., Kivitz, A.J., Fleischmann, R.M., Inman, R.D., Ni, L., Lin, S.L., Tsuji, W.H. Ann. Rheum. Dis. (2008) [Pubmed]
  2. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Davis, J.C., Revicki, D., van der Heijde, D.M., Rentz, A.M., Wong, R.L., Kupper, H., Luo, M.P. Arthritis Rheum. (2007) [Pubmed]
  3. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Davis, J.C. Semin. Arthritis Rheum. (2005) [Pubmed]
  4. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Davis, J.C., van der Heijde, D.M., Braun, J., Dougados, M., Cush, J., Clegg, D., Inman, R.D., Kivitz, A., Zhou, L., Solinger, A., Tsuji, W. Ann. Rheum. Dis. (2005) [Pubmed]
  5. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Davis, J.C., van der Heijde, D., Dougados, M., Woolley, J.M. Arthritis Rheum. (2005) [Pubmed]
  6. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. Davis, J.C., Van der Heijde, D.M., Dougados, M., Braun, J., Cush, J.J., Clegg, D.O., Inman, R.D., de Vries, T., Tsuji, W.H. J. Rheumatol. (2005) [Pubmed]
  7. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Davis, J.C., Huang, F., Maksymowych, W. Rheum. Dis. Clin. North Am. (2003) [Pubmed]
  8. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Davis, J.C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D.O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W. Arthritis Rheum. (2003) [Pubmed]
  9. The role of etanercept in ankylosing spondylitis. Davis, J.C. Clin. Exp. Rheumatol. (2002) [Pubmed]
  10. A practical approach to gout. Current management of an 'old' disease. Davis, J.C. Postgrad. Med (1999) [Pubmed]
 
WikiGenes - Universities